Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-38431055 + sitagliptin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-38431055 + sitagliptin is an investigational combination therapy for type 2 diabetes mellitus. JNJ-38431055 (also known as APD-597) is a small molecule agonist of the G protein-coupled receptor 119 (GPR119), developed to enhance incretin secretion and improve glycemic control. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous levels of incretin hormones such as GLP-1 and GIP by inhibiting their degradation, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. The combination aims to leverage complementary mechanisms—JNJ-38431055 stimulates incretin release while sitagliptin prolongs their activity—to improve blood glucose regulation in patients with type 2 diabetes[2][5][7]. Both drugs are orally administered small molecules.
- Other names
- APD-597APD597APD 597JNJ38431055JNJ-38431055JNJ 38431055
02
Targets
GPR119 (Glucose-dependent insulinotropic receptor)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on JNJ-38431055 + sitagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-38431055 + sitagliptin.